Overview

A Phase I/IIa Study of Safety, Tolerability and Plasma Concentration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients

Status:
Completed

Trial end date:
2013-09-01

Target enrollment:

Participant gender:

Summary

In this Phase I/IIa study, the effect of continuous subcutaneous administration of LD/CD solution (ND0612) on the safety and PK profile of LD will be examined.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

NeuroDerm Ltd.

Treatments:

Carbidopa
Levodopa
Pharmaceutical Solutions